Vaccinex (VCNX) – Investment Research Analysts’ Latest Ratings Changes

Vaccinex (VCNX) – Investment Research Analysts’ Latest Ratings Changes

Several analysts have recently updated their ratings and price targets for Vaccinex (NASDAQ: VCNX):

12/26/2018 – Vaccinex was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Vaccinex, Inc. is a clinical-stage immunotherapy company. It engages in the discovery and development of biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The company’s product pipeline consists of VX15, VX5 and VX25 which are in clinical stage. Vaccinex, Inc. is based in Rochester, New York. “

12/19/2018 – Vaccinex was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Vaccinex, Inc. is a clinical-stage immunotherapy company. It engages in the discovery and development of biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The company’s product pipeline consists of VX15, VX5 and VX25 which are in clinical stage. Vaccinex, Inc. is based in Rochester, New York. “

12/13/2018 – Vaccinex was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Vaccinex, Inc. is a clinical-stage immunotherapy company. It engages in the discovery and development of biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The company’s product pipeline consists of VX15, VX5 and VX25 which are in clinical stage. Vaccinex, Inc. is based in Rochester, New York. “

12/6/2018 – Vaccinex was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Vaccinex, Inc. is a clinical-stage immunotherapy company. It engages in the discovery and development of biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The company’s product pipeline consists of VX15, VX5 and VX25 which are in clinical stage. Vaccinex, Inc. is based in Rochester, New York. “

11/29/2018 – Vaccinex was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Vaccinex, Inc. is a clinical-stage immunotherapy company. It engages in the discovery and development of biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The company’s product pipeline consists of VX15, VX5 and VX25 which are in clinical stage. Vaccinex, Inc. is based in Rochester, New York. “

11/17/2018 – Vaccinex was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Vaccinex, Inc. is a clinical-stage immunotherapy company. It engages in the discovery and development of biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The company’s product pipeline consists of VX15, VX5 and VX25 which are in clinical stage. Vaccinex, Inc. is based in Rochester, New York. “

11/13/2018 – Vaccinex was given a new $22.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.

VCNX traded down $0.10 during trading hours on Thursday, hitting $3.94. 2,600 shares of the company’s stock were exchanged, compared to its average volume of 15,979. Vaccinex Inc has a 12-month low of $3.80 and a 12-month high of $12.00.

Vaccinex (NASDAQ:VCNX) last announced its earnings results on Tuesday, November 13th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.29). The company had revenue of $0.20 million for the quarter. On average, research analysts forecast that Vaccinex Inc will post -4.46 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc purchased a new stake in Vaccinex during the 3rd quarter worth approximately $341,000. Vanguard Group Inc. purchased a new stake in Vaccinex during the 3rd quarter worth approximately $341,000. Nexthera Capital LP purchased a new stake in Vaccinex during the 3rd quarter worth approximately $124,000. Perceptive Advisors LLC purchased a new stake in Vaccinex during the 3rd quarter worth approximately $365,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Vaccinex in the 3rd quarter valued at approximately $124,000. 2.17% of the stock is currently owned by hedge funds and other institutional investors.

Vaccinex, Inc operates as a clinical-stage biotechnology company. It engages in the discovery and development of bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is VX15 that is in Phase Ib/II clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer, osteosarcoma, and melanoma; and Phase II clinical trials for the treatment of Huntington's disease.

Featured Article: Are all No-Load Funds Equal?

Related posts

Leave a Comment